Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

DRUG(2)

Standard of Care Endocrine Therapy

2 unique interventions1 categories

Analytics

Trial Phases

Phase 11

Phase 21

Trial Status

Recruiting1

Role Distribution

Other Roles1

Activity Timeline

Clinical Trials (1)

NCT06590857Phase 1/2Recruiting

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Advanced Breast CancerBone Metastases in Subjects With Advanced Breast CancerER-Positive HER2-Negative Breast Cancer+7 more

StudydirectorStart date: 2024-07-19

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Advanced Breast Cancer1 Bone Metastases in Subjects With Advanced Breast Cancer1 ER+ Breast Cancer1 ER-Positive HER2-Negative Breast Cancer1 Estrogen Receptor-positive Breast Cancer1 HER2-negative Breast Cancer1 Hormone-Sensitive Breast Cancer1 Hormone-sensitive Metastatic Breast Cancer1

Affiliations

RayzeBio, Inc.

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Ingrid Mayer, MD

Vanderbilt-Ingram Cancer Center

13 trials

Shared therapeutic areas:

Hormone-sensitive Metastatic Breast CancerMetastatic Breast Cancer

Similarity Score6%

Herui Yao, PhD

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

11 trials

Shared therapeutic areas:

Metastatic Breast CancerAdvanced Breast Cancer

Similarity Score6%

Xichun Hu, MD, PhD

Fudan University

14 trials

Shared therapeutic areas:

Metastatic Breast CancerAdvanced Breast Cancer

Similarity Score6%

Project Leader

Ono Pharmaceutical Co., Ltd.

47 trials

Shared therapeutic areas:

HER2-negative Breast CancerMetastatic Breast Cancer

Similarity Score6%

Scott Holden, M.D.

Genentech, Inc.

8 trials

Shared therapeutic areas:

Metastatic Breast Cancer

Similarity Score3%

Jaymes Holland

Alaunos Therapeutics

8 trials

Shared therapeutic areas:

Metastatic Breast Cancer

Similarity Score3%

Zhong-yu Yuan, M.D.

Sun Yat-sen University

9 trials

Shared therapeutic areas:

Metastatic Breast Cancer

Similarity Score3%

Andrea de Matteis, M.D.

NCI Naples, Division of Medical Oncology C

7 trials

Shared therapeutic areas:

Metastatic Breast Cancer

Similarity Score3%

Priyanka Sharma, MD

University of Kansas Medical Center

8 trials

Shared therapeutic areas:

Metastatic Breast Cancer

Similarity Score3%

Hope S. Rugo, MD

University of California, San Francisco

10 trials

Shared therapeutic areas:

Metastatic Breast Cancer

Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT06590857Phase 1/2StudyDirector

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Advanced Breast CancerBone Metastases in Subjects With Advanced Breast CancerER-Positive HER2-Negative Breast Cancer+7 more

Recruiting

All 1 trials loaded